InMode (INMD) has released an update.
InMode Ltd., a key player in medical technology, has reported a significant decline in its second-quarter revenue for 2024, with a 36.5% drop to $86.4 million compared to the previous year. Despite the downturn, the company remains optimistic due to strong interest and pre-orders for its new platforms, Ignite and Optimus Max, and has completed a $150 million share repurchase program. With a revised full-year 2024 revenue outlook of $430 to $440 million, InMode anticipates that these new platforms will be pivotal in driving future growth.
For further insights into INMD stock, check out TipRanks’ Stock Analysis page.
